Aurobindo Pharma Limited (NSE: AUROPHARMA, BSE: 524804) announced its consolidated financial results for the quarter ended June 30, 2026, reporting revenue from operations of INR 9,150 crore, a 16.3% increase year-over-year, driven by growth across its businesses including an 8.1% rise in US revenue to INR 3,770 crore and a 25.6% increase in Europe revenue to INR 2,937 crore. The company’s net profit for the quarter stood at INR 1,032 crore, while its free cash flow reached USD 98 million, and it held a strong net cash position of USD 42 million after investments including the Lannett acquisition and a share buyback. Aurobindo Pharma also received final approval for 10 products from the USFDA.
